To acquire more insights on this unmet medical issue, we conducted the present study aiming to evaluate the impact of adding a taxane, using endocrine therapy as well as carrying a deleterious germline BRCA mutation on the ovarian reserve measured by AMH levels at baseline and up to 3 years after diagnosis in young early breast cancer patients treated with (neo)adjuvant anthracycline- and cyclophosphamide-based chemotherapy. Here, AMH is linked to breast carcinoma.